Summary
Chemotherapy can cause significant damage to healthy tissues, especially in the hematopoietic system. As a result, cancer survivors may experience bone marrow damage manifested as cytopenias, which increase the risk of infections and bleeding. Despite this, there has not been a thorough examination of these events, including the clonal dynamics of hematopoiesis after chemotherapy exposure, due to a lack of methodologies to perform lineage tracing in humans in vivo. To address this, I will study the effects of chemotherapy on the clonal dynamics of hematopoiesis, mitochondrial dysfunction and genetic integrity in young cancer survivors. I will analyze samples obtained before, during, and after treatment using emerging single-cell multi-omic approaches to effectively capture mitochondrial DNA (mtDNA) genetic variation for inferences of clonal dynamics and studies of mtDNA damage. By combining mtDNA-based clonal inferences with whole-genome sequencing (WGS)-based detection of somatic nuclear DNA mutations, I will provide deep phylogenies with scalable single-cell resolved clonal measurements of perturbed hematopoiesis following chemotherapy. Moreover, orthogonal analysis of DNA methylation and chromatin accessibility data will yield new molecular insights into chemotherapy-induced accelerated aging and mitochondrial dysfunction (a hallmark of aging). This project sets out to gain quantitative and fundamental insights into the long-term molecular defects of chemotherapy in young cancer survivors, potentially paving the way for new interventions to improve the quality of life of this emergent population.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101150135 |
| Start date: | 01-12-2024 |
| End date: | 30-11-2026 |
| Total budget - Public funding: | - 189 687,00 Euro |
Cordis data
Original description
Chemotherapy can cause significant damage to healthy tissues, especially in the hematopoietic system. As a result, cancer survivors may experience bone marrow damage manifested as cytopenias, which increase the risk of infections and bleeding. Despite this, there has not been a thorough examination of these events, including the clonal dynamics of hematopoiesis after chemotherapy exposure, due to a lack of methodologies to perform lineage tracing in humans in vivo. To address this, I will study the effects of chemotherapy on the clonal dynamics of hematopoiesis, mitochondrial dysfunction and genetic integrity in young cancer survivors. I will analyze samples obtained before, during, and after treatment using emerging single-cell multi-omic approaches to effectively capture mitochondrial DNA (mtDNA) genetic variation for inferences of clonal dynamics and studies of mtDNA damage. By combining mtDNA-based clonal inferences with whole-genome sequencing (WGS)-based detection of somatic nuclear DNA mutations, I will provide deep phylogenies with scalable single-cell resolved clonal measurements of perturbed hematopoiesis following chemotherapy. Moreover, orthogonal analysis of DNA methylation and chromatin accessibility data will yield new molecular insights into chemotherapy-induced accelerated aging and mitochondrial dysfunction (a hallmark of aging). This project sets out to gain quantitative and fundamental insights into the long-term molecular defects of chemotherapy in young cancer survivors, potentially paving the way for new interventions to improve the quality of life of this emergent population.Status
SIGNEDCall topic
HORIZON-MSCA-2023-PF-01-01Update Date
21-11-2024
Images
No images available.
Geographical location(s)
